A Merck Sharp & Dohme LLC patent details new GTPase KRAS and its G12C, G12D, G12V and/or G13D mutant inhibitors reported to be useful for the treatment of cancer.
The Research Foundation of State University of New York and the U.S. Department of Health and Human Services have jointly developed prazole-based compounds acting as H+/K+-ATPase inhibitors and thus reported to be useful for the treatment of viral infections.
Arrepath Inc. has patented new UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors reported to be useful for the treatment of gram-negative bacterial infections.
Researchers from Osaka University have developed a novel approach to target nicotinamide N-methyltransferase (NNMT), an enzyme implicated in cancer progression, using antisense oligonucleotides (ASOs).
Traditional neoantigen prediction methods primarily rely on HLA-peptide binding databases, often producing false positives. This challenge highlights the need for improved strategies to identify truly immunogenic neoantigens. Neoantigen-based cancer vaccines have shown promising efficacy in recent clinical trials for treating solid tumors, offering a potential solution.
Both IL-15 and IL-2 are good options for cancer therapy, but IL-15 is considered superior due to lower vascular endothelial toxicity, stronger ability to expand natural killer and CD8+ T cells and weaker stimulation of T regulatory cells, but it has a short half-life and exerts severe adverse effects.
Researchers at Jilin University and collaborators combed through data in the public Cancer Genome Atlas and identified a potential target for lung adenocarcinoma.
KAT6A and its paralogue KAT6B are histone acetyltransferases whose overexpression is linked to poor prognosis in ER+/HER2- breast cancer and other types of tumors.
A recent study explored the therapeutic potential of hu128.1, a humanized antibody targeting transferrin receptor 1 (TfR1), in treating erythroleukemia using xenograft mouse models. The results demonstrate that hu128.1 exerts strong antitumor activity against human erythroleukemic (ERY-1) cells, highlighting its promise as a candidate for managing this aggressive cancer.
Indivior plc has successfully advanced its GABA-B positive allosteric modulator (PAM) program for substance use disorders through IND-enabling studies with the completion of the last preclinical safety and toxicity studies.
RSS
